Esperion Therapeutics (ESPR) Research & Development (2012 - 2026)

Esperion Therapeutics' Research & Development history runs 15 years deep, the most recent figure standing at $9.0 million for Q1 2026.

• Quarterly Research & Development fell 28.42% year-over-year to $9.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.3 million (down 2.44% YoY) and the FY2025 annual result came in at $47.9 million, up 3.49% from the prior year.
• Research & Development was $9.0 million for Q1 2026 at Esperion Therapeutics, down from $13.9 million in the prior quarter.
• Across five years, Research & Development topped out at $33.0 million in Q4 2022 and bottomed at $7.2 million in Q2 2025.
• A 5-year average of $18.1 million and a median of $14.1 million in 2025 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2024 — Research & Development plunged 57.29% — and 2025, when it soared 35.91%.
• Esperion Therapeutics' Research & Development stood at $33.0 million in 2022, then plunged by 46.29% to $17.7 million in 2023, then plunged by 38.13% to $11.0 million in 2024, then increased by 26.87% to $13.9 million in 2025, then sank by 35.46% to $9.0 million in 2026.
• Business Quant data shows ESPR's Research & Development at $9.0 million in Q1 2026, $13.9 million in Q4 2025, and $14.1 million in Q3 2025.